Reed, Camp Good Days Make Cancer Research Push
Rep. Tom Reed and Gary Mervis of Camp Good Days and Special Times are teaming up to end cancer by the end of the decade with a push for the Clinical Trial Cancer Mission 2020 Act. Reed and Gary Mervis, Chairman and Founder of Camp Good Days, collaborated to craft the legislation strengthening reporting requirements for cancer research.
“Raising awareness for the Clinical Trial Cancer Mission 2020 legislation Gary and I worked to advance is a constant effort,” Reed said. “Every week, 11,000 Americans die from cancer. We need to all be on the same page and working together to give patients a fair chance at beating cancer. Making clinical trial results available to all researchers will help improve care, increase the chances of finding a cure and protect taxpayers from funding duplicative research.”
“There is no better time than now to create the will in American people to put cancer on the front burner,” said Mervis. “Clinical Trial Cancer Mission 2020 will not only save money, but it will save time spent with the unnecessary duplication of research. You can learn just as much from research that fails as research that succeeds. If scientists and researchers know about prior experiments, they can tweak their work and adjust to previous findings.”
The lack of enforcement in reporting clinical trial results led Reed to work with Camp Good Days to draft and introduce the Clinical Trials Cancer Mission 2020 legislation to make it mandatory for researchers to publish all data from clinical studies, whether the results are positive or negative. The bill establishes a national clearinghouse, under the auspices of the National Institute of Health (NIH) and includes penalties for researchers who do not comply. Reed and Mervis plan to solicit feedback from the nation’s top cancer centers and clinical trial stakeholders this year.
Last month Reed announced a $1.2 billion research funding increase for the National Institutes of Health (NIH), with Reed saying critical research dollars are needed in the efforts to end cancer by the end of the decade. In addition to the increased funding levels, Reed helped to secure a clinical trial workshop within the NIH.
“This workshop has been tasked with exploring innovative and more consistent and reliable ways to track and monitor clinical trials,” Reed continued. “Thanks in large part to the support from my New York colleagues on our clinical trial legislation, we will all benefit from the workshop’s findings due to Congress this September.”
In June, Reed and Mervis visited the Falck Cancer Center at Arnot Health to announce the reintroduction of Reed’s legislation to strengthen cancer research reporting requirements. Details from the announcement can be found here.